Antiandrogen withdrawal syndrome with cyproterone acetate

Urology

Volumn 52, Issue 6, 1998, Pages 1091-1093

  Sella, A ^a   Flex, D ^a   Sulkes, A ^b   Baniel, J ^b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; KETOCONAZOLE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; CASTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; WITHDRAWAL SYNDROME;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; CYPROTERONE ACETATE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0032400811     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00354-9     Document Type: Article

References (15)

1. Scher H.I., Kelly K. Flutamide withdrawal syndrome its impact on clinical trials in hormone-refractory prostate cancer . J Clin Oncol. 11:1993;1566-1572.
2. Small E.J., Srinivas S. The antiandrogen withdrawal syndrome Experience in a large cohort of unselected patients treated with advanced prostate cancer . Cancer. 76:1995;1428-1434.
3. Scher H.I., Liebertz C., Kelly K., et al. Bicalutamide for advanced prostate cancer the natural versus treated history of disease . J Clin Oncol. 8:1997;2928-2938.
4. Nieh P.T. Withdrawal phenomenon with the antiandrogen Casodex. J Urol. 153:1995;1070-1073.
5. Huan S.D., Gerridzen R.G., Yau Y.C., et al. Antiandrogen withdrawal syndrome with nilutamide. Urology. 49:1997;632-634.
6. Dawson N.A., McLeod D.G. Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer expansion of the antiandrogen withdrawal syndrome . J Urol. 153:1995;1946-1947.
7. Pavone-Macaluso M., Ingargiola G.B., de Voogt H., et al. Cyproterone acetate versus medroxyprogesterone acetate versus diethylstilbestrol in the treatment of prostate cancer results from EORTC study 30761 . Murphy G.P., Khoury S., Küss Chaatelain C., et al. Progress in Clinical and Biological Research. vol 243A:1986;379-382 Liss, New York.
8. Crawford E.A. Editorial comments. J Urol. 153:1995;1072.
9. Akakura K., Akimoto S., Ohki T., et al. Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate. Urology. 45:1995;700-704.
10. Veldschole J., Berrevoets C.A., Brinkmann A.O., et al. Anti-androgens and the mutated androgen receptor of LNCaP cells differential effects on binding affinity, heat shock protein interaction, and transcription activation . Biochemistry. 31:1992;2392-2399.
11. Wilding G., Chen M., Gelman E.P. Aberrant response in-vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate. 14:1989;103-115.
12. Sartor O., Cooper M., Weinberger M., et al. Surprising activity of flutamide withdrawal combined with aminogluthetimide in treatment of "hormone-refractory" prostate cancer. J Natl Cancer Inst. 86:1994;222-227.
13. Visakorpi T., Hyytinen E., Kovisito P., et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genet. 9:1995;401-406.
14. Robin J., Fenton M.A., Rode P., et al. High dose bicalutamide for androgen independent prostate cancer effect of prior hormonal therapy . J Urol. 159:1998;149-153.
15. 3 prostate cancer. Proc Annu Meet Am Soc Clin Oncol. 33:1997;1116.